摘要
目的测定Graves病（GD）患者血小板膜糖蛋白CD62P、CD63的表达及在抗甲状腺药物治疗过程中的变化，并探讨其临床意义。方法30例GD患者分别在治疗前、治疗2月和6月时用放射免疫法测定血清TSH、FT3、FT4，采用流式细胞仪检测血浆CD62P、CD63阳性表达率，30例年龄与性别相匹配的健康志愿者作为正常对照。结果GD患者治疗前的FT3、FT4值显著高于对照组（P〈0.01），GD组的TSH显著低于对照组（P〈0．01）；GD患者的治疗前CD62P、CD63阳性表达率均显著高于对照组，治疗后2个月及6个月均逐渐下降，但仍高于对照组；GD患者治疗前CD62P、CD63的表达与FT3、FT4呈正相关（r=0．38、0．29、0．33、0．24，P均〈0．05），而与TSH无明显相关。结论GD患者血浆CD62P、CD63的异常与GD的发生发展密切关联，在治疗前后的变化能反映出GD病情的严重程度和治疗效果，在临床上随访CD62P、CD63的阳性表达率的变化将有助于监测病情的转归。
Objective To study the expression levels of CD62P and CD63 in GD through measurement of their changes during antithyroid drug treatment. Method Serum TSH, FT3 and FT4 levels of 30 cases GD patients at the time of diagnosis and after 2 and 6 months of treatment were measured by immunoradiometric assay; the expression levels of CD62P and CD63 were measured by FCM; 30 cases age and sex matched healthy subjects were served as controls. Results （1）Compared with normal control , the levels of FT3 and FT4 in GD were significantly elevated （ P 〈0. 001 ）, while the levels of TSH were deceased drastically （ P 〈0. 001 ）. （2）The positive expression rate of CD62P and CD63 in GD was higher than that of normal control at the time of diagnosis. The positive expression rate of CD62P and CD63 in GD started to drop after 2 months of treatment, but it was eventually higher than that of normal control after 6 months of treatment. （3）correlation analysis showed that CD62P,CD63 were positively correlated to FT3 （ r = 0.38 and 0. 29, P 〈 0. 05）, FT4 （ r = 0. 33 and 0. 24, P 〈 0. 05） before starting treatment, but there was no statistical correlation between CD62P, CD63 and TSH. Conclusion The expressions of CD62P and CD63 may play an important role in the pathogenesis and progression of GD, and might reflect the immune activity and be implicated in immunopathology and prognosis of the disease.
出处
《中国医师杂志》
CAS
2007年第4期492-494,共3页
Journal of Chinese Physician
